How CMOs Can Meet Demands For Data In Life Sciences

The life sciences industry is entering a new in medicine development, propelled by advances in science and technology. As research methodologies progress and promising prospects emerge, innovative cell and gene therapies are becoming more available. Medical progress is driven by and drives the industry as it continues to experience robust growth. In 2023, the pharmaceutical market was valued at USD 1.6 trillion, with a projected CAGR of 6.4% expected through 2030.

Central to this growth are CMOs and CDMOs. While CMOs produce pre-formulated products according to client specifications, CDMOs often research and develop new drug formulations in addition to this. Both offer flexibility, speed-to-market, economies of scale, and resilience to the life sciences industry by delivering specialized services in drug development, formulation, manufacturing, and packaging.

This white paper provides vital insights for leaders of CMO and CDMO organizations aiming to navigate their digitalization journey effectively. It also offers valuable guidance for life sciences customers who utilize their services or are contemplating doing so. To be part of the growth forecast, CMOs and CDMOs must address the increasing demand from clients for enhanced visibility into the manufacturing process. Failure to meet this demand could result in being marginalized in this competitive landscape.